STOCK TITAN

4D Molecular Therapeutics, Inc. - $FDMT STOCK NEWS

Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: $FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 4D Molecular Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 4D Molecular Therapeutics's position in the market.

-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
4D Molecular Therapeutics, Inc.

Nasdaq:FDMT

FDMT Rankings

FDMT Stock Data

1.37B
31.64M
3.53%
85.52%
18.72%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
EMERYVILLE

About FDMT

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim